XNYS
ABT
Market cap170bUSD
Oct 08, Last price
98.49USD
1D
-0.24%
1Q
4.85%
Jan 2017
156.42%
Name
Abbott Laboratories
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Abbott Laboratories, a global healthcare company operating through its various subsidiaries, is committed to the research, development, production, and sale of a diverse portfolio of health-related products worldwide. Its operations are structured into four main divisions: The Established Pharmaceutical Products segment offers generic medications for a broad spectrum of conditions. These include treatments for pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis, depressive symptoms, gynecological disorders, and hormone replacement therapy. It also provides solutions for dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, as well as pain, fever, inflammation, and migraines. Key offerings further extend to the anti-infective clarithromycin, an influenza vaccine, and products designed to regulate the physiological rhythm of the colon. The Diagnostic Products segment delivers a comprehensive range of diagnostic tools and systems. This includes laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion medicine. It also features molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, alongside detecting and measuring infectious agents. Further offerings encompass point-of-care systems, blood test cartridges, rapid lateral flow testing products, and molecular point-of-care testing for various conditions like HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. The segment also supplies cardiometabolic test systems, drug and alcohol testing solutions, remote patient monitoring, consumer self-test systems, and advanced informatics and automation solutions for laboratory applications. The Nutritional Products division specializes in providing a variety of nutritional items for both children and adults. Finally, the Medical Devices segment develops and markets advanced medical technologies, primarily focusing on cardiovascular health with devices for rhythm management, electrophysiology, heart failure, vascular interventions, and structural heart conditions. This segment also offers diabetes care products and neuromodulation devices used in the management of chronic pain and movement disorders. Abbott Laboratories was established in 1888 and is headquartered in North Chicago, Illinois.
Related entities
Subsidiaries (140)
ABBOTT MEDICAL (MALAYSIA) SDN. BHD.
Abbott Medical (Schweiz) AG
Abbott Medical (Shanghai) Co., Ltd.
ABBOTT MEDICAL (SINGAPORE), PTE. LTD.
ABBOTT MEDICAL (THAILAND) COMPANY LIMITED
ABBOTT MEDICAL AUSTRALIA PTY LTD.
ABBOTT MEDICAL BALKAN DOO BEOGRAD (NOVI BEOGRAD)
ABBOTT MEDICAL CANADA CO.
ABBOTT MEDICAL COSTA RICA LIMITADA
ABBOTT MEDICAL DEVICES TRADING (SHANGHAI) CO., LTD.
ABBOTT MEDICAL FRANCE SAS
Abbott Medical GmbH
Abbott Medical Italia S.R.L.
ABBOTT MEDICAL JAPAN LLC
Abbott Medical Korea Limited
ABBOTT MEDICAL NEW ZEALAND LIMITED
Abbott Medical Sweden AB
ABBOTT MEDICAL TAIWAN CO.
ABBOTT PRODUCTS (PHILIPPINES), INC.
Abbott Products Operations AG
Key people
Robert Ford
Chairman of the Board, Chief Executive Officer · since 2021
Philip Boudreau
Chief Financial Officer, Executive Vice President - Finance · since 2024
Hubert Allen
Executive Vice President, General Counsel, Secretary · since 2013
Lisa Earnhardt
Executive Vice President, Group President - Medical Devices · since 2023
Mary Moreland
Executive Vice President - Human Resources · since 2019
Louis Morrone
Executive Vice President - Core Diagnostics · since 2023
Daniel Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products · since 2021
Andrea Wainer
Executive Vice President - Rapid and Molecular Diagnostics · since 2019
Randel Woodgrift
Senior Vice President - Cardio Rhythm Management · since 2019
John Mccoy
Vice President - Finance, Controller · since 2023
Nita Ahuja
Director · since 2025
Independent Director · since 2008
Claire Babineaux-Fontenot
Independent Director · since 2022
Sally Blount
Independent Director · since 2011
Patricia Gonzalez
Independent Director · since 2021
Independent Director · since 2018
Independent Director · since 2019
Lead Independent Director · since 2023
Michael O'Grady
Independent Director · since 2023
Michael Roman
Independent Director · since 2021
Legal address
C/O C T CORPORATION SYSTEM
208 SO LASALLE ST
SUITE 814
CHICAGO, IL 60604
US
208 SO LASALLE ST
SUITE 814
CHICAGO, IL 60604
US
Headquarters
100 Abbott Park Road
AP6D-2 D312
Abbott Park
Green Oaks, IL 60064
US
AP6D-2 D312
Abbott Park
Green Oaks, IL 60064
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||